Author Archives: Patricia Inacio PhD

Retrotope’s Experimental RT001 Now Available for ALS Under Expanded Access Program

Retrotope is providing its investigational fatty acid being developed for Friedreich’s ataxia, RT001, to people with amyotrophic lateral sclerosis (ALS) under an expanded access program, also called “compassionate use.” Individual patients with life-threatening or severely debilitating diseases can petition the U.S. Food and Drug Administration, through their physicians,…

Phase 3 Trial of Oral Levosimendan as Respiratory Treatment for ALS Recruiting in US, Europe and Australia

A new Phase 3 trial evaluating levosimendan (also known as ODM-109), an oral treatment by Orion for breathing problems in amyotrophic lateral sclerosis (ALS), has recruited its first patients, the Finnish pharmaceutical company announced. The trial, called REFALS (NCT03505021), aims to investigate the potential benefits of prolonged treatment with levosimendan…

Prediction Model May Help Personalize Survival Prognosis in ALS Patients, Researchers Say

Researchers have developed a personalized, non-invasive model that uses a set of characteristics, easily obtained at diagnosis, to predict survival in patients with amyotrophic lateral sclerosis (ALS). The study with that finding, “Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model,” was published…